HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	12/11/2003 5:58:23 AM
From: nigel bates	Read Replies (1) of 1022

Just parking (hadn't noticed them before): aeresbiomedical.com AERES is recognised internationally for the practise of antibody humanization via CDR-grafting and has a clear track record of success in the field. Working with biotech and pharmaceutical companies from throughout the World, AERES has successfully humanized 23 antibodies, retaining both antibody affinity and specificity in the process. No less than 6 therapeutic antibody candidates developed for our collaborative research partners are currently in the clinic. These include Antegren™ which is being co-developed, by Biogen (USA) and Elan Pharmaceuticals (USA/Eire), to treat multiple sclerosis and Crohns disease. Antegren™ is expected to reach the market in 2005. A number of other humanized antibodies developed for our partners are in Phase I/II clinical trials or advanced pre-clinical development. Aside from its humanization activities, AERES has generated many mammalian cell lines on behalf of its partners producing recombinant antibodies for both research use and for potential manufacture. Recent collaborators include the National Cancer Institute (USA) and Acorda Therapeutics (USA)...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next